PH22018000418U1 - Monovalent manilae vaccine against locally prevalent leptospira serovar in the philippines - Google Patents

Monovalent manilae vaccine against locally prevalent leptospira serovar in the philippines

Info

Publication number
PH22018000418U1
PH22018000418U1 PH22018000418U PH22018000418U PH22018000418U1 PH 22018000418 U1 PH22018000418 U1 PH 22018000418U1 PH 22018000418 U PH22018000418 U PH 22018000418U PH 22018000418 U PH22018000418 U PH 22018000418U PH 22018000418 U1 PH22018000418 U1 PH 22018000418U1
Authority
PH
Philippines
Prior art keywords
manilae
vaccines
philippines
monovalent
losbanos
Prior art date
Application number
PH22018000418U
Other versions
PH22018000418Y1 (en
Inventor
Nina G Gloriani
Sharon Yvette Angelina M Villanueva
Shin-Ichi Yoshida
Yasutake Yanagihara
Original Assignee
Univ Of The Philippines Manila
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of The Philippines Manila filed Critical Univ Of The Philippines Manila
Priority to PH22018000418U priority Critical patent/PH22018000418Y1/en
Publication of PH22018000418U1 publication Critical patent/PH22018000418U1/en
Publication of PH22018000418Y1 publication Critical patent/PH22018000418Y1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present technology relates to processes of preparing leptospirosis vaccines against serovars or serotypes of Leptospira prevalent in the Philippines. Three types of inactivated vaccines were developed based on two identified most prevalent pathogenic Leptospira serovars circulating in the Philippines, namely, Manilae and Losbanos. The vaccines that have been developed are: (1) Monovalent Manilae, (2) Monovalent Losbanos, and (3) Bivalent Manilae and Losbanos (homologous challenge with serovars Manilae and Losbanos and heterochallenge with serovar Grippotyphosa and serovar Canicola). The vaccines that were produced through the developed process were assessed on their safety, immunogenicity and efficiency. The main advantage of these vaccines is their serovar-specificity for the pathogenic Leptospira serovars that are locally prevalent which would ensure an effectively directed program of preventive control of leptospirosis in animals which can be translated to effective leptospirosis prevention among humans.
PH22018000418U 2018-05-15 2018-05-15 Monovalent manilae vaccine against locally prevalent leptospira serovar in the philippines PH22018000418Y1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PH22018000418U PH22018000418Y1 (en) 2018-05-15 2018-05-15 Monovalent manilae vaccine against locally prevalent leptospira serovar in the philippines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PH22018000418U PH22018000418Y1 (en) 2018-05-15 2018-05-15 Monovalent manilae vaccine against locally prevalent leptospira serovar in the philippines

Publications (2)

Publication Number Publication Date
PH22018000418U1 true PH22018000418U1 (en) 2020-04-22
PH22018000418Y1 PH22018000418Y1 (en) 2020-04-22

Family

ID=71112219

Family Applications (1)

Application Number Title Priority Date Filing Date
PH22018000418U PH22018000418Y1 (en) 2018-05-15 2018-05-15 Monovalent manilae vaccine against locally prevalent leptospira serovar in the philippines

Country Status (1)

Country Link
PH (1) PH22018000418Y1 (en)

Also Published As

Publication number Publication date
PH22018000418Y1 (en) 2020-04-22

Similar Documents

Publication Publication Date Title
NZ595914A (en) Vaccines comprising attenuated mycoplasma bovis strains and method for the attenuation
PE20140576A1 (en) BOVINE VACCINES AND METHODS
NZ591950A (en) Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
PE20170243A1 (en) VACCINE COMPOSITIONS WITH DUAL ADJUVANT, PREPARATION AND USES
MX2013010620A (en) Non-pathogenic serotype 4 fowl adenovirus (fadv-4) and viral vector thereof.
MX2018010958A (en) Live attenuated zika virus vaccine.
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
BR112015005056A2 (en) combination vaccines with meningococcus serogroup b and d / t / p
CL2016002402A1 (en) Immunological compositions containing histophilus somni attenuated
MX2018015506A (en) Vaccine against infectious bronchitis virus.
PH12018500305A1 (en) Multivalent vlp conjugates
CL2008003845A1 (en) Vaccine comprising an emulsion, a bacterin heat-treated at 55-70 ° C for 5-10 hours, comprising a suspension of killed bacteria of the leptospira bratislava species, and from 1 to 13 viruses that cause swine disease.
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
BR112016007390A2 (en) haemophilus parasuis serotype type four vaccine
EA201892003A1 (en) TREATMENT OF ATOPIC DERMATITIS DOGS
PH22018000417Y1 (en) Monovalent losbanos vaccine against locally prevalent leptospira serovar in the philippines
PH22018000416U1 (en) Bivalent manilae and losbanos vaccine against locally prevalent leptospira serovars in the philippines
PH22018000418U1 (en) Monovalent manilae vaccine against locally prevalent leptospira serovar in the philippines
AR093424A1 (en) ATTACHED VACCINES OF HAEMOLYTIC MANNHEIMIA AND METHODS FOR THEIR ELABORATION AND USE
MX362420B (en) Polyvalent fusion protein vaccine against influenza.
CO6160333A2 (en) BATTERIES TREATED WITH HEAT AND EMULSION VACCINES PREPARED FROM THESE BATTERIES TREATED WITH HEAT
MX2021015938A (en) Porcine reproductive and respiratory syndrome vaccine virus.
EA202090236A1 (en) IMMUNOGENIC COMPOSITIONS OF SENECAVIRUS A AND WAYS WITH THEM
UA127237U (en) Pig Leptospirosis Vaccine (SUIS Option)
UA127236U (en) LIPTOSPIROSIS VACCINE POLYVALENT (BOVIS OPTION)